Enhancement of radiation response of prostatic carcinoma by lonidamine

Scott D. Dudak, Armando Lopez, Norman L. Block, Bal L. Lokeshwar

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Potential application of lonidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2 depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model consistent with its in vitro effect on the same cell fine. LND did not alter the primary growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

Original languageEnglish (US)
Pages (from-to)3665-3672
Number of pages8
JournalAnticancer research
Volume16
Issue number6 B
StatePublished - Dec 1 1996

Keywords

  • Adjuvant therapy
  • Lonidamine
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Enhancement of radiation response of prostatic carcinoma by lonidamine'. Together they form a unique fingerprint.

  • Cite this

    Dudak, S. D., Lopez, A., Block, N. L., & Lokeshwar, B. L. (1996). Enhancement of radiation response of prostatic carcinoma by lonidamine. Anticancer research, 16(6 B), 3665-3672.